Astonea Labs Ltd vs Remus Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Astonea Labs Ltd is ₹ 160.05 as of 30 Apr 15:30 . The P/E Ratio of Astonea Labs Ltd is 0 as of March 2024 .The P/E Ratio of Remus Pharmaceuticals Ltd is 49.4 as of March 2024 . The Market Cap of Astonea Labs Ltd is ₹ 0 crore as of March 2024 .The Market Cap of Remus Pharmaceuticals Ltd is ₹ 1016 crore as of March 2024 . The Dividend Payout of Astonea Labs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Remus Pharmaceuticals Ltd changed from 2.56 % on March 2023 to 4.44 % on March 2025 . This represents a CAGR of 20.15% over 3 years .

About Astonea Labs Ltd

Astonea Labs Limited was originally incorporated as 'AHU Laboratories Private Limited', as a private limited company, pursuant to certificate of incorporation dated April 11, 2017.
Company changed its name from AHU Laboratories Limited to 'Astonea Labs Private Limited' dated February 26, 2019.
Subsequently, the Company further changed the name to 'Astonea Labs Limited', vide fresh Certificate of Incorporation dated January 11, 2024. Company specializes in the manufacturing and marketing of a wide range of pharmaceutical and cosmetic products.
These include antibiotic drugs, anticold medications, antihistamines, and drugs for diabetes, cardiovascular diseases, gynecological concerns, analgesics, fungal infections, and multivitamins.
These are used for skin, tooth, and hair care, available in various forms such as gels, ointments, creams, lotions, oils, and serums.

About Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat.
Subsequently, Company converted from a Private to Public and the name of the Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad. The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs.
It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

FAQs for the comparison of Astonea Labs Ltd and Remus Pharmaceuticals Ltd

Which company has a larger market capitalization, Astonea Labs Ltd or Remus Pharmaceuticals Ltd?

Market cap of Astonea Labs Ltd is 168 Cr while Market cap of Remus Pharmaceuticals Ltd is 807 Cr

What are the key factors driving the stock performance of Astonea Labs Ltd and Remus Pharmaceuticals Ltd?

The stock performance of Astonea Labs Ltd and Remus Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astonea Labs Ltd and Remus Pharmaceuticals Ltd?

As of May 4, 2026, the Astonea Labs Ltd stock price is INR ₹160.05. On the other hand, Remus Pharmaceuticals Ltd stock price is INR ₹685.3.

How do dividend payouts of Astonea Labs Ltd and Remus Pharmaceuticals Ltd compare?

To compare the dividend payouts of Astonea Labs Ltd and Remus Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.